Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)
Frequently Asked Questions Research References Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017) Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004) Regeneration or Risk
Protect your skin: Keep your skin away from direct sunlight and employ only the recommended skincare products
Injection technique with 5mg vials Drawing the dose Reconstituted with 2ml water (2,500mcg/ml): 250mcg = 10 units 500mcg = 20 units Process : Wipe vial top with alcohol Draw air into syringe (same amount as dose) Inject air into vial Invert vial Draw solution slowly Remove needle, check for air bubbles Tap syringe to remove bubbles Injection sites Best locations for subcutaneous injection: Abdomen (2 inches from belly button) Front of thigh Back of upper arm (harder to self-inject) Site-specific injection (optional): Can inject near injury site for localized effect
Currently, the standard of care does not include injecting or prescribing unapproved experimental peptides for injuries there is no FDA approval or authoritative guideline endorsing BPC-157 use
P., Smolle, J., Smolle-Juettner, F